Key statistics dashboard for MetaVia Inc. (MTVA). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH).
Stock Data
| Price | $1.54 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.38 |
| Price / Book | 1.34 |
| P/S | 0.00 |
| P/FCF | -0.21 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 2.06 |
| Quick Ratio | 2.06 |
| Cash Ratio | 1.99 |
| Debt / Equity | 0.03 |
| Debt / Assets | 1.33% |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 1.15 |
| Cash per share | 2.13 |
| FCF per share | -2.67 |
| Tangible Book Value per share | 1.15 |
| Dividend per share | 0.00 |
Related companies: CASI · CLGN · CLSD · ENLV · KLTO · LSTA · NCNA
Explore sector: Healthcare · Biotechnology
More sections of MTVA: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks